Texas A&M Researchers Detail Groundbreaking Angelman Syndrome Development

A new publication explains the novel science behind the first molecular therapeutic for the rare neurogenetic disorder to advance into clinical development.

By Jennifer Gauntt, VMBS Communications – March 22, 2023